Joenja (Leniolisib Phosphate) Patent Expiration, LOE Window & CMS Spending

Joenja (Leniolisib Phosphate) by Pharming Technologies Bv: FDA Orange Book core substance LOE 2032-02-19, 0 AB generics, $22.6M 2024 CMS Part D & Medicaid spend, and $45,000 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorPharming Technologies Bv
FDA Application & PathwayN217759 (NDA)
Exclusivity / Cliff HorizonMid-Term Protection (2031-2035)
Core Active-Ingredient LOE Date2032-02-19
Last Listed Patent or Exclusivity Date2032-02-19
Orange Book Patents (*PED Extensions)1 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$22.6M
2024 Medicare Part D Spend$3.9M
2024 Medicaid Spend$18.7M
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($45,000 intro WAC)